Zhejiang Ausun Pharmaceutical Co Ltd (603229) - Net Assets
Based on the latest financial reports, Zhejiang Ausun Pharmaceutical Co Ltd (603229) has net assets worth CN¥2.37 Billion CNY (≈ $346.39 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.16 Billion ≈ $461.94 Million USD) and total liabilities (CN¥789.65 Million ≈ $115.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603229 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.37 Billion |
| % of Total Assets | 74.99% |
| Annual Growth Rate | 51.38% |
| 5-Year Change | 80.85% |
| 10-Year Change | 832.73% |
| Growth Volatility | 68.06 |
Zhejiang Ausun Pharmaceutical Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Zhejiang Ausun Pharmaceutical Co Ltd (603229) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual net assets of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025. For live valuation and market cap data, see 603229 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.27 Billion ≈ $332.08 Million |
-0.11% |
| 2024-12-31 | CN¥2.27 Billion ≈ $332.45 Million |
+6.08% |
| 2023-12-31 | CN¥2.14 Billion ≈ $313.38 Million |
+46.57% |
| 2022-12-31 | CN¥1.46 Billion ≈ $213.81 Million |
+16.44% |
| 2021-12-31 | CN¥1.25 Billion ≈ $183.62 Million |
+11.35% |
| 2020-12-31 | CN¥1.13 Billion ≈ $164.90 Million |
+74.66% |
| 2019-12-31 | CN¥645.19 Million ≈ $94.41 Million |
+7.96% |
| 2018-12-31 | CN¥597.60 Million ≈ $87.45 Million |
+5.78% |
| 2017-12-31 | CN¥564.93 Million ≈ $82.67 Million |
+132.19% |
| 2016-12-31 | CN¥243.30 Million ≈ $35.60 Million |
+29.37% |
| 2015-12-31 | CN¥188.07 Million ≈ $27.52 Million |
+140.48% |
| 2014-12-31 | CN¥78.21 Million ≈ $11.44 Million |
+137.66% |
| 2013-12-31 | CN¥32.91 Million ≈ $4.82 Million |
+217.78% |
| 2012-12-31 | CN¥10.36 Million ≈ $1.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Ausun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42517.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥903.47 Million | 39.81% |
| Other Components | CN¥1.37 Billion | 60.19% |
| Total Equity | CN¥2.27 Billion | 100.00% |
Zhejiang Ausun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Ausun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Henan Ancai Hi-tech Co Ltd
SHG:600207
|
$986.69 Million |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
$986.88 Million |
|
AMAG Austria Metall AG
VI:AMAG
|
$987.39 Million |
|
SK ETERNIX CO LT
KO:475150
|
$987.52 Million |
|
BIRLASOFT LIMITED
NSE:BSOFT
|
$986.56 Million |
|
Healthcare Global Enterprises Limited
NSE:HCG
|
$986.47 Million |
|
Sinodata Co Ltd
SHE:002657
|
$986.25 Million |
|
Everlight Electronics Co Ltd
TW:2393
|
$986.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Ausun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,271,891,202 to 2,269,358,214, a change of -2,532,988 (-0.1%).
- Net income of 130,570,124 contributed positively to equity growth.
- Dividend payments of 90,623,944 reduced retained earnings.
- Other comprehensive income increased equity by 832,491.
- Other factors decreased equity by 43,311,659.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥130.57 Million | +5.75% |
| Dividends Paid | CN¥90.62 Million | -3.99% |
| Other Comprehensive Income | CN¥832.49K | +0.04% |
| Other Changes | CN¥-43.31 Million | -1.91% |
| Total Change | CN¥- | -0.11% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Ausun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 65.81x to 2.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.12 | CN¥8.12 | x |
| 2013-12-31 | CN¥0.22 | CN¥8.12 | x |
| 2014-12-31 | CN¥0.50 | CN¥8.12 | x |
| 2015-12-31 | CN¥0.53 | CN¥8.12 | x |
| 2016-12-31 | CN¥0.62 | CN¥8.12 | x |
| 2017-12-31 | CN¥1.20 | CN¥8.12 | x |
| 2018-12-31 | CN¥1.12 | CN¥8.12 | x |
| 2019-12-31 | CN¥1.22 | CN¥8.12 | x |
| 2020-12-31 | CN¥2.15 | CN¥8.12 | x |
| 2021-12-31 | CN¥2.24 | CN¥8.12 | x |
| 2022-12-31 | CN¥2.60 | CN¥8.12 | x |
| 2023-12-31 | CN¥2.61 | CN¥8.12 | x |
| 2024-12-31 | CN¥2.75 | CN¥8.12 | x |
| 2025-12-31 | CN¥2.73 | CN¥8.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Ausun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.75%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.47%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.36x
- Recent ROE (5.75%) is below the historical average (17.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 22.15% | 3.89% | 0.48x | 11.84x | CN¥1.26 Million |
| 2013 | 47.26% | 12.86% | 0.68x | 5.43x | CN¥12.26 Million |
| 2014 | 27.49% | 10.67% | 0.77x | 3.33x | CN¥13.68 Million |
| 2015 | 32.36% | 23.17% | 0.65x | 2.14x | CN¥42.06 Million |
| 2016 | 23.56% | 28.83% | 0.45x | 1.83x | CN¥33.00 Million |
| 2017 | 9.38% | 22.07% | 0.32x | 1.31x | CN¥-3.48 Million |
| 2018 | 7.34% | 17.99% | 0.30x | 1.34x | CN¥-15.90 Million |
| 2019 | 8.74% | 18.31% | 0.35x | 1.37x | CN¥-8.13 Million |
| 2020 | 7.71% | 21.22% | 0.30x | 1.23x | CN¥-25.85 Million |
| 2021 | 11.63% | 25.62% | 0.31x | 1.47x | CN¥20.45 Million |
| 2022 | 16.11% | 30.79% | 0.33x | 1.58x | CN¥89.26 Million |
| 2023 | 11.86% | 31.09% | 0.28x | 1.38x | CN¥39.74 Million |
| 2024 | 9.10% | 26.00% | 0.27x | 1.31x | CN¥-20.40 Million |
| 2025 | 5.75% | 16.47% | 0.26x | 1.36x | CN¥-96.37 Million |
Industry Comparison
This section compares Zhejiang Ausun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical Co Ltd (603229) | CN¥2.37 Billion | 22.15% | 0.33x | $986.57 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more